Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b6 Bivalent
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BNT162b6 Bivalent** is an investigational BioNTech/Pfizer RNA-based COVID-19 vaccine candidate evaluated as a 30-microgram bivalent formulation encoding SARS-CoV-2 spike antigens from the ancestral original strain and the Omicron BA.4/BA.5 lineage. It is one of several distinct BNT162b candidates designed with differing prefusion-stabilized spike versions. The vaccine is intended to induce spike-specific neutralizing antibody and cellular immune responses for prevention of COVID-19. It was studied in Cohort 4 of the completed Phase 1/2/3 C4591044 trial in COVID-19-vaccine-experienced healthy adults. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/38/NCT05472038/Prot_000.pdf))
- Other names
- BNT162b6 Bivalent Original OMI BA.4 BA.5BNT-162b6 Bivalent Original OMI BA.4 BA.5BNT 162b6 Bivalent Original OMI BA.4 BA.5
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)
Beyond the preview
Go deeper on BNT162b6 Bivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b6 Bivalent.